5 completed, 3 terminated, 2 not yet recruiting, 1 withdrawn. 9 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 3, Terminated 3, Not yet recruiting 2, Withdrawn 1 |
| Phase 1 | 5 | Completed 2, Terminated 2, Not yet recruiting 1 |
Follow Telaglenastat: new trials by email Literature Review of Telaglenastat trials Research Report on Telaglenastat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer Telaglenastat, Radiation treatment, Cisplatin - Advanced Cervical Carcinoma, Cervical Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 42 | 2026-12-31 | 2026-09-03 |
| TEPH: Telaglenastat Efficacy in Pulmonary Hypertension Telaglenastat - Pulmonary Hypertension | Phase 1 / Phase 2 | Not yet recruiting | Chan, Stephen, MD, PhD | 28 | 2026-11-01 | 2026-09-17 |
| Telaglenastat + Talazoparib In Prostate Cancer Telaglenastat, Talazoparib - Prostate Cancer Metastatic | Phase 2 | Withdrawn | Massachusetts General Hospital | 2021-07-01 | 2026-10-20 | |
| Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects telaglenastat, telaglenastat placebo, moxifloxicin - Cardiac Safety | Phase 1 | Completed | Calithera Biosciences, Inc | 30 | 2020-10-05 | 2021-03-09 |
| Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects Telaglenastat, Famotidine, Placebo for famotidine - Drug Interaction | Phase 1 | Completed | Calithera Biosciences, Inc | 22 | 2020-09-22 | 2021-03-09 |
| KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy - Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer | Phase 2 | Terminated | Calithera Biosciences, Inc | 40 | 2020-07-24 | 2022-09-21 |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors CB-839, Talazoparib - Solid Tumor, Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Calithera Biosciences, Inc | 33 | 2019-05-20 | 2022-02-17 |
| CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma CB-839, Cabozantinib, Placebo - Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Completed | Calithera Biosciences, Inc | 444 | 2018-04-24 | 2023-03-20 |
| CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) Placebo, CB-839, everolimus - Clear Cell Renal Cell Carcinoma | Phase 2 | Completed | Calithera Biosciences, Inc | 69 | 2017-09-06 | 2022-09-15 |
| Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) Paclitaxel, CB-839 - Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Completed | Calithera Biosciences, Inc | 52 | 2017-05-01 | 2022-09-28 |
| Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) CB-839, Nivolumab - Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma | Phase 1 / Phase 2 | Terminated | Calithera Biosciences, Inc | 118 | 2016-08-01 | 2023-03-17 |
Carcinoma, Renal Cell (4) · Carcinoma, Non-Small-Cell Lung (2) · Triple Negative Breast Neoplasms (2) · Colorectal Neoplasms (1) · Hypertension, Pulmonary (1) · Kidney Neoplasms (1) · Lung Diseases (1) · Melanoma (1) · Uterine Cervical Neoplasms (1)
Calithera Biosciences, Inc (8) · Chan, Stephen, MD, PhD (1) · Massachusetts General Hospital (1) · Washington University School of Medicine (1)
United States (9) · Australia (2) · United Kingdom (2) · France (1) · Germany (1) · Italy (1) · New Zealand (1) · Spain (1)
Sam Whiting, MD, PhD (3) · Emil Kuriakose, MD (1) · Julie K Schwarz, M.D., Ph.D. (1) · Michael Risbano, MD (1) · Paul Griffin, Dr. (1) · Richard J Lee, MD, PhD (1) · Sam Whiting (1) · Sam Whiting, M.D., Ph.D. (1) · Sunu Valasseri, MD (1)
PMID 39462179, PMID 35576438, PMID 36048457
R01CA181745 (1)